#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=Obesity and vitamin-D deficiency are two major global public health concerns that affect over one-third of the population .
3-1	16-23	Obesity	abstract	new	coref	9-18
3-2	24-27	and	_	_	_	_
3-3	28-37	vitamin-D	substance|abstract[4]	new|new[4]	coref|coref	3-6[6_4]|4-15
3-4	38-48	deficiency	abstract[4]	new[4]	_	_
3-5	49-52	are	_	_	_	_
3-6	53-56	two	abstract[6]	giv[6]	coref	5-10[18_6]
3-7	57-62	major	abstract[6]	giv[6]	_	_
3-8	63-69	global	abstract[6]	giv[6]	_	_
3-9	70-76	public	abstract[5]|abstract[6]	new[5]|giv[6]	coref	18-20[134_5]
3-10	77-83	health	abstract[5]|abstract[6]	new[5]|giv[6]	_	_
3-11	84-92	concerns	abstract[6]	giv[6]	_	_
3-12	93-97	that	abstract[6]	giv[6]	_	_
3-13	98-104	affect	abstract[6]	giv[6]	_	_
3-14	105-109	over	abstract[6]	giv[6]	_	_
3-15	110-119	one-third	abstract[6]	giv[6]	_	_
3-16	120-122	of	abstract[6]	giv[6]	_	_
3-17	123-126	the	abstract[6]|person[7]	giv[6]|new[7]	_	_
3-18	127-137	population	abstract[6]|person[7]	giv[6]|new[7]	_	_
3-19	138-139	.	_	_	_	_

#Text=A body mass index of more than 30 kg/m2 is associated with lower serum vitamin-D levels compared with non-obese individuals .
4-1	140-141	A	abstract[10]	new[10]	coref	17-16[121_10]
4-2	142-146	body	object|abstract[9]|abstract[10]	new|new[9]|new[10]	coref	20-6[148_0]
4-3	147-151	mass	abstract[9]|abstract[10]	new[9]|new[10]	_	_
4-4	152-157	index	abstract[10]	new[10]	_	_
4-5	158-160	of	abstract[10]	new[10]	_	_
4-6	161-165	more	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-7	166-170	than	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-8	171-173	30	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-9	174-179	kg/m2	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-10	180-182	is	_	_	_	_
4-11	183-193	associated	_	_	_	_
4-12	194-198	with	_	_	_	_
4-13	199-204	lower	abstract[14]	new[14]	coref	7-11[27_14]
4-14	205-210	serum	abstract|abstract[14]	new|new[14]	coref	15-11
4-15	211-220	vitamin-D	substance|abstract[14]	giv|new[14]	coref	8-31
4-16	221-227	levels	abstract[14]	new[14]	_	_
4-17	228-236	compared	_	_	_	_
4-18	237-241	with	_	_	_	_
4-19	242-251	non-obese	person[15]	new[15]	coref	7-5[26_15]
4-20	252-263	individuals	person[15]	new[15]	_	_
4-21	264-265	.	_	_	_	_

#Text=Several mechanisms that contribute to the high incidence of vitamin-D deficiency in obese people were suggested .
5-1	266-273	Several	abstract[16]	new[16]	coref	9-35[56_16]
5-2	274-284	mechanisms	abstract[16]	new[16]	_	_
5-3	285-289	that	abstract[16]	new[16]	_	_
5-4	290-300	contribute	abstract[16]	new[16]	_	_
5-5	301-303	to	abstract[16]	new[16]	_	_
5-6	304-307	the	abstract[16]|abstract[17]	new[16]|new[17]	_	_
5-7	308-312	high	abstract[16]|abstract[17]	new[16]|new[17]	_	_
5-8	313-322	incidence	abstract[16]|abstract[17]	new[16]|new[17]	_	_
5-9	323-325	of	abstract[16]|abstract[17]	new[16]|new[17]	_	_
5-10	326-335	vitamin-D	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|giv[18]	coref	9-3[45_18]
5-11	336-346	deficiency	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|giv[18]	_	_
5-12	347-349	in	abstract[16]|abstract[17]	new[16]|new[17]	_	_
5-13	350-355	obese	abstract[16]|abstract[17]|person[19]	new[16]|new[17]|new[19]	_	_
5-14	356-362	people	abstract[16]|abstract[17]|person[19]	new[16]|new[17]|new[19]	_	_
5-15	363-367	were	_	_	_	_
5-16	368-377	suggested	_	_	_	_
5-17	378-379	.	_	_	_	_

#Text=Ultraviolet radiation from sunlight exposure is required for cutaneous production of vitamin D.
6-1	380-391	Ultraviolet	abstract[20]	new[20]	ana	7-1[0_20]
6-2	392-401	radiation	abstract[20]	new[20]	_	_
6-3	402-406	from	abstract[20]	new[20]	_	_
6-4	407-415	sunlight	abstract[20]|substance|event[22]	new[20]|new|new[22]	coref|coref	7-30[31_22]|7-33
6-5	416-424	exposure	abstract[20]|event[22]	new[20]|new[22]	_	_
6-6	425-427	is	_	_	_	_
6-7	428-436	required	_	_	_	_
6-8	437-440	for	_	_	_	_
6-9	441-450	cutaneous	abstract[23]	new[23]	coref	23-24[185_23]
6-10	451-461	production	abstract[23]	new[23]	_	_
6-11	462-464	of	abstract[23]	new[23]	_	_
6-12	465-472	vitamin	abstract[23]|substance[24]	new[23]|new[24]	coref	7-14[28_24]
6-13	473-475	D.	abstract[23]|substance[24]	new[23]|new[24]	_	_

#Text=It was proposed that obese individuals , overall , have suboptimal levels of vitamin D because they tend to participate in fewer outdoor activities and , accordingly , have less exposure to sunlight .
7-1	476-478	It	abstract	giv	_	_
7-2	479-482	was	_	_	_	_
7-3	483-491	proposed	_	_	_	_
7-4	492-496	that	_	_	_	_
7-5	497-502	obese	person[26]	giv[26]	ana	7-17[0_26]
7-6	503-514	individuals	person[26]	giv[26]	_	_
7-7	515-516	,	_	_	_	_
7-8	517-524	overall	_	_	_	_
7-9	525-526	,	_	_	_	_
7-10	527-531	have	_	_	_	_
7-11	532-542	suboptimal	abstract[27]	giv[27]	coref	15-10[96_27]
7-12	543-549	levels	abstract[27]	giv[27]	_	_
7-13	550-552	of	abstract[27]	giv[27]	_	_
7-14	553-560	vitamin	abstract[27]|substance[28]	giv[27]|giv[28]	coref	8-1[33_28]
7-15	561-562	D	abstract[27]|substance[28]	giv[27]|giv[28]	_	_
7-16	563-570	because	_	_	_	_
7-17	571-575	they	person	giv	coref	8-20[39_0]
7-18	576-580	tend	_	_	_	_
7-19	581-583	to	_	_	_	_
7-20	584-595	participate	_	_	_	_
7-21	596-598	in	_	_	_	_
7-22	599-604	fewer	event[30]	new[30]	_	_
7-23	605-612	outdoor	event[30]	new[30]	_	_
7-24	613-623	activities	event[30]	new[30]	_	_
7-25	624-627	and	_	_	_	_
7-26	628-629	,	_	_	_	_
7-27	630-641	accordingly	_	_	_	_
7-28	642-643	,	_	_	_	_
7-29	644-648	have	_	_	_	_
7-30	649-653	less	event[31]	giv[31]	_	_
7-31	654-662	exposure	event[31]	giv[31]	_	_
7-32	663-665	to	event[31]	giv[31]	_	_
7-33	666-674	sunlight	event[31]|substance	giv[31]|giv	_	_
7-34	675-676	.	_	_	_	_

#Text=Vitamin D is a lipid-soluble vitamin , and it is thought that the lower bioavailability of vitamin D in obese individuals , compared to lean individuals , is due to vitamin-D sequestration within the adipose tissues .
8-1	677-684	Vitamin	substance[33]	giv[33]	coref	8-4[34_33]
8-2	685-686	D	substance[33]	giv[33]	_	_
8-3	687-689	is	_	_	_	_
8-4	690-691	a	substance[34]	giv[34]	ana	8-9[0_34]
8-5	692-705	lipid-soluble	substance[34]	giv[34]	_	_
8-6	706-713	vitamin	substance[34]	giv[34]	_	_
8-7	714-715	,	_	_	_	_
8-8	716-719	and	_	_	_	_
8-9	720-722	it	substance	giv	coref	8-17
8-10	723-725	is	_	_	_	_
8-11	726-733	thought	_	_	_	_
8-12	734-738	that	_	_	_	_
8-13	739-742	the	abstract[36]	new[36]	_	_
8-14	743-748	lower	abstract[36]	new[36]	_	_
8-15	749-764	bioavailability	abstract[36]	new[36]	_	_
8-16	765-767	of	abstract[36]	new[36]	_	_
8-17	768-775	vitamin	abstract[36]|substance|substance[38]	new[36]|giv|giv[38]	coref|coref	8-17[38_0]|9-16[0_38]
8-18	776-777	D	abstract[36]|substance[38]	new[36]|giv[38]	_	_
8-19	778-780	in	abstract[36]	new[36]	_	_
8-20	781-786	obese	abstract[36]|person[39]	new[36]|giv[39]	coref	8-25[40_39]
8-21	787-798	individuals	abstract[36]|person[39]	new[36]|giv[39]	_	_
8-22	799-800	,	_	_	_	_
8-23	801-809	compared	_	_	_	_
8-24	810-812	to	_	_	_	_
8-25	813-817	lean	person[40]	giv[40]	coref	27-17[224_40]
8-26	818-829	individuals	person[40]	giv[40]	_	_
8-27	830-831	,	_	_	_	_
8-28	832-834	is	_	_	_	_
8-29	835-838	due	_	_	_	_
8-30	839-841	to	_	_	_	_
8-31	842-851	vitamin-D	substance|abstract[42]	giv|new[42]	coref	10-6
8-32	852-865	sequestration	abstract[42]	new[42]	_	_
8-33	866-872	within	abstract[42]	new[42]	_	_
8-34	873-876	the	abstract[42]|object[44]	new[42]|new[44]	coref	20-14[150_44]
8-35	877-884	adipose	abstract[42]|abstract|object[44]	new[42]|new|new[44]	coref	25-27
8-36	885-892	tissues	abstract[42]|object[44]	new[42]|new[44]	_	_
8-37	893-894	.	_	_	_	_

#Text=Lastly , vitamin-D deficiency may also be due to inadequate dietary intake or malabsorption of vitamin D. Obesity is a well-established risk factor for the development of cardiovascular disease ( CVD ) , and several mechanisms may contribute to this link .
9-1	895-901	Lastly	_	_	_	_
9-2	902-903	,	_	_	_	_
9-3	904-913	vitamin-D	abstract[45]	giv[45]	coref	10-6[60_45]
9-4	914-924	deficiency	abstract[45]	giv[45]	_	_
9-5	925-928	may	_	_	_	_
9-6	929-933	also	_	_	_	_
9-7	934-936	be	_	_	_	_
9-8	937-940	due	_	_	_	_
9-9	941-943	to	_	_	_	_
9-10	944-954	inadequate	abstract[46]	new[46]	coref	16-9[103_46]
9-11	955-962	dietary	abstract[46]	new[46]	_	_
9-12	963-969	intake	abstract[46]	new[46]	_	_
9-13	970-972	or	_	_	_	_
9-14	973-986	malabsorption	abstract[47]	new[47]	_	_
9-15	987-989	of	abstract[47]	new[47]	_	_
9-16	990-997	vitamin	abstract[47]|substance|person[49]	new[47]|giv|new[49]	coref	11-6
9-17	998-1000	D.	abstract[47]|person[49]	new[47]|new[49]	_	_
9-18	1001-1008	Obesity	abstract	giv	coref	9-20[52_0]
9-19	1009-1011	is	_	_	_	_
9-20	1012-1013	a	abstract[52]	giv[52]	coref	28-15[0_52]
9-21	1014-1030	well-established	abstract[52]	giv[52]	_	_
9-22	1031-1035	risk	abstract|abstract[52]	new|giv[52]	coref	10-9[64_0]
9-23	1036-1042	factor	abstract[52]	giv[52]	_	_
9-24	1043-1046	for	abstract[52]	giv[52]	_	_
9-25	1047-1050	the	abstract[52]|event[53]	giv[52]|new[53]	_	_
9-26	1051-1062	development	abstract[52]|event[53]	giv[52]|new[53]	_	_
9-27	1063-1065	of	abstract[52]|event[53]	giv[52]|new[53]	_	_
9-28	1066-1080	cardiovascular	abstract[52]|event[53]|abstract[54]	giv[52]|new[53]|new[54]	appos	9-31[0_54]
9-29	1081-1088	disease	abstract[52]|event[53]|abstract[54]	giv[52]|new[53]|new[54]	_	_
9-30	1089-1090	(	_	_	_	_
9-31	1091-1094	CVD	abstract	giv	coref	13-17
9-32	1095-1096	)	_	_	_	_
9-33	1097-1098	,	_	_	_	_
9-34	1099-1102	and	_	_	_	_
9-35	1103-1110	several	abstract[56]	giv[56]	_	_
9-36	1111-1121	mechanisms	abstract[56]	giv[56]	_	_
9-37	1122-1125	may	_	_	_	_
9-38	1126-1136	contribute	_	_	_	_
9-39	1137-1139	to	_	_	_	_
9-40	1140-1144	this	abstract[57]	new[57]	_	_
9-41	1145-1149	link	abstract[57]	new[57]	_	_
9-42	1150-1151	.	_	_	_	_

#Text=However , a role of vitamin-D deficiency in obesity-associated cardiovascular ( CV ) risk is yet to be established .
10-1	1152-1159	However	_	_	_	_
10-2	1160-1161	,	_	_	_	_
10-3	1162-1163	a	abstract[58]	new[58]	_	_
10-4	1164-1168	role	abstract[58]	new[58]	_	_
10-5	1169-1171	of	abstract[58]	new[58]	_	_
10-6	1172-1181	vitamin-D	abstract[58]|substance|abstract[60]	new[58]|giv|giv[60]	coref|coref	11-6[69_60]|14-1
10-7	1182-1192	deficiency	abstract[58]|abstract[60]	new[58]|giv[60]	_	_
10-8	1193-1195	in	abstract[58]	new[58]	_	_
10-9	1196-1214	obesity-associated	abstract[58]|abstract|abstract[64]	new[58]|new|giv[64]	coref	14-6[89_64]
10-10	1215-1229	cardiovascular	abstract[58]|object|abstract[64]	new[58]|new|giv[64]	_	_
10-11	1230-1231	(	abstract[58]|abstract[64]	new[58]|giv[64]	_	_
10-12	1232-1234	CV	abstract[58]|abstract|abstract[64]	new[58]|new|giv[64]	_	_
10-13	1235-1236	)	abstract[58]|abstract[64]	new[58]|giv[64]	_	_
10-14	1237-1241	risk	abstract[58]|abstract[64]	new[58]|giv[64]	_	_
10-15	1242-1244	is	_	_	_	_
10-16	1245-1248	yet	_	_	_	_
10-17	1249-1251	to	_	_	_	_
10-18	1252-1254	be	_	_	_	_
10-19	1255-1266	established	_	_	_	_
10-20	1267-1268	.	_	_	_	_

#Text=Epidemiological data reported associations between vitamin D deficiency and left ventricular hypertrophy , hypertension , increased arterial stiffness , and endothelial dysfunction .
11-1	1269-1284	Epidemiological	abstract[65]	new[65]	_	_
11-2	1285-1289	data	abstract[65]	new[65]	_	_
11-3	1290-1298	reported	_	_	_	_
11-4	1299-1311	associations	abstract[66]	new[66]	coref	12-5[75_66]
11-5	1312-1319	between	abstract[66]	new[66]	_	_
11-6	1320-1327	vitamin	abstract[66]|substance|abstract[69]	new[66]|giv|giv[69]	coref|coref	13-11|13-25[84_69]
11-7	1328-1329	D	abstract[66]|person|abstract[69]	new[66]|new|giv[69]	coref	13-11[79_0]
11-8	1330-1340	deficiency	abstract[66]|abstract[69]	new[66]|giv[69]	_	_
11-9	1341-1344	and	abstract[66]	new[66]	_	_
11-10	1345-1349	left	abstract[66]|abstract[70]	new[66]|new[70]	_	_
11-11	1350-1361	ventricular	abstract[66]|abstract[70]	new[66]|new[70]	_	_
11-12	1362-1373	hypertrophy	abstract[66]|abstract[70]	new[66]|new[70]	_	_
11-13	1374-1375	,	abstract[66]	new[66]	_	_
11-14	1376-1388	hypertension	abstract[66]|abstract	new[66]|new	coref	13-28
11-15	1389-1390	,	abstract[66]	new[66]	_	_
11-16	1391-1400	increased	abstract[66]|abstract[72]	new[66]|new[72]	coref	17-22[123_72]
11-17	1401-1409	arterial	abstract[66]|abstract[72]	new[66]|new[72]	_	_
11-18	1410-1419	stiffness	abstract[66]|abstract[72]	new[66]|new[72]	_	_
11-19	1420-1421	,	abstract[66]	new[66]	_	_
11-20	1422-1425	and	abstract[66]	new[66]	_	_
11-21	1426-1437	endothelial	abstract[66]|abstract[73]	new[66]|new[73]	coref	23-21[183_73]
11-22	1438-1449	dysfunction	abstract[66]|abstract[73]	new[66]|new[73]	_	_
11-23	1450-1451	.	_	_	_	_

#Text=The pathophysiological underpinnings of these associations remain mostly unexplained .
12-1	1452-1455	The	abstract[74]	new[74]	_	_
12-2	1456-1474	pathophysiological	abstract[74]	new[74]	_	_
12-3	1475-1488	underpinnings	abstract[74]	new[74]	_	_
12-4	1489-1491	of	abstract[74]	new[74]	_	_
12-5	1492-1497	these	abstract[74]|abstract[75]	new[74]|giv[75]	_	_
12-6	1498-1510	associations	abstract[74]|abstract[75]	new[74]|giv[75]	_	_
12-7	1511-1517	remain	_	_	_	_
12-8	1518-1524	mostly	_	_	_	_
12-9	1525-1536	unexplained	_	_	_	_
12-10	1537-1538	.	_	_	_	_

#Text=The most reliable and convincing evidence for the involvement of vitamin D in the pathogenesis of CVD comes from studies demonstrating an association between vitamin-D deficiency and hypertension .
13-1	1539-1542	The	abstract[76]	new[76]	coref	24-2[186_76]
13-2	1543-1547	most	abstract[76]	new[76]	_	_
13-3	1548-1556	reliable	abstract[76]	new[76]	_	_
13-4	1557-1560	and	abstract[76]	new[76]	_	_
13-5	1561-1571	convincing	abstract[76]	new[76]	_	_
13-6	1572-1580	evidence	abstract[76]	new[76]	_	_
13-7	1581-1584	for	abstract[76]	new[76]	_	_
13-8	1585-1588	the	abstract[76]|abstract[77]	new[76]|new[77]	_	_
13-9	1589-1600	involvement	abstract[76]|abstract[77]	new[76]|new[77]	_	_
13-10	1601-1603	of	abstract[76]|abstract[77]	new[76]|new[77]	_	_
13-11	1604-1611	vitamin	abstract[76]|abstract[77]|substance|person[79]	new[76]|new[77]|giv|giv[79]	coref|coref	18-16|18-16[133_79]
13-12	1612-1613	D	abstract[76]|abstract[77]|person[79]	new[76]|new[77]|giv[79]	_	_
13-13	1614-1616	in	abstract[76]|abstract[77]	new[76]|new[77]	_	_
13-14	1617-1620	the	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
13-15	1621-1633	pathogenesis	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
13-16	1634-1636	of	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
13-17	1637-1640	CVD	abstract[76]|abstract[77]|abstract[80]|abstract	new[76]|new[77]|new[80]|giv	coref	23-17
13-18	1641-1646	comes	_	_	_	_
13-19	1647-1651	from	_	_	_	_
13-20	1652-1659	studies	abstract[82]	new[82]	coref	21-1[156_82]
13-21	1660-1673	demonstrating	abstract[82]	new[82]	_	_
13-22	1674-1676	an	abstract[82]|abstract[83]	new[82]|new[83]	coref	15-3[93_83]
13-23	1677-1688	association	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-24	1689-1696	between	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-25	1697-1706	vitamin-D	abstract[82]|abstract[83]|abstract[84]|abstract[85]	new[82]|new[83]|giv[84]|new[85]	coref|coref	14-1[88_84]|23-14[181_85]
13-26	1707-1717	deficiency	abstract[82]|abstract[83]|abstract[84]|abstract[85]	new[82]|new[83]|giv[84]|new[85]	_	_
13-27	1718-1721	and	abstract[82]|abstract[83]|abstract[85]	new[82]|new[83]|new[85]	_	_
13-28	1722-1734	hypertension	abstract[82]|abstract[83]|abstract[85]|abstract	new[82]|new[83]|new[85]|giv	coref	14-18
13-29	1735-1736	.	_	_	_	_

#Text=Vitamin-D deficiency is associated with a higher risk for preeclampsia , a condition that is characterized by hypertension .
14-1	1737-1746	Vitamin-D	substance|abstract[88]	giv|giv[88]	coref|coref	15-10|23-14[180_88]
14-2	1747-1757	deficiency	abstract[88]	giv[88]	_	_
14-3	1758-1760	is	_	_	_	_
14-4	1761-1771	associated	_	_	_	_
14-5	1772-1776	with	_	_	_	_
14-6	1777-1778	a	abstract[89]	giv[89]	_	_
14-7	1779-1785	higher	abstract[89]	giv[89]	_	_
14-8	1786-1790	risk	abstract[89]	giv[89]	_	_
14-9	1791-1794	for	abstract[89]	giv[89]	_	_
14-10	1795-1807	preeclampsia	abstract[89]|event	giv[89]|new	_	_
14-11	1808-1809	,	_	_	_	_
14-12	1810-1811	a	abstract[91]	new[91]	_	_
14-13	1812-1821	condition	abstract[91]	new[91]	_	_
14-14	1822-1826	that	abstract[91]	new[91]	_	_
14-15	1827-1829	is	abstract[91]	new[91]	_	_
14-16	1830-1843	characterized	abstract[91]	new[91]	_	_
14-17	1844-1846	by	abstract[91]	new[91]	_	_
14-18	1847-1859	hypertension	abstract[91]|abstract	new[91]|giv	coref	17-30
14-19	1860-1861	.	_	_	_	_

#Text=Also , a significant inverse association was reported between vitamin-D serum levels and arterial blood pressure in the elderly .
15-1	1862-1866	Also	_	_	_	_
15-2	1867-1868	,	_	_	_	_
15-3	1869-1870	a	abstract[93]	giv[93]	coref	23-11[178_93]
15-4	1871-1882	significant	abstract[93]	giv[93]	_	_
15-5	1883-1890	inverse	abstract[93]	giv[93]	_	_
15-6	1891-1902	association	abstract[93]	giv[93]	_	_
15-7	1903-1906	was	_	_	_	_
15-8	1907-1915	reported	_	_	_	_
15-9	1916-1923	between	_	_	_	_
15-10	1924-1933	vitamin-D	substance|abstract[96]|abstract[97]	giv|giv[96]|giv[97]	coref|coref	15-10[97_96]|16-9
15-11	1934-1939	serum	abstract|abstract[96]|abstract[97]	giv|giv[96]|giv[97]	_	_
15-12	1940-1946	levels	abstract[96]|abstract[97]	giv[96]|giv[97]	_	_
15-13	1947-1950	and	abstract[97]	giv[97]	_	_
15-14	1951-1959	arterial	abstract[97]|abstract[99]	giv[97]|new[99]	coref	16-35[112_99]
15-15	1960-1965	blood	abstract[97]|substance|abstract[99]	giv[97]|new|new[99]	coref	21-17
15-16	1966-1974	pressure	abstract[97]|abstract[99]	giv[97]|new[99]	_	_
15-17	1975-1977	in	abstract[97]|abstract[99]	giv[97]|new[99]	_	_
15-18	1978-1981	the	abstract[97]|abstract[99]	giv[97]|new[99]	_	_
15-19	1982-1989	elderly	abstract[97]|abstract[99]	giv[97]|new[99]	_	_
15-20	1990-1991	.	_	_	_	_

#Text=An interventional study demonstrated that one month of vitamin-D intake ( 1,5000 IU/day ) reduced tissue sensitivity to the stimulation of the renin – angiotensin system manifested by improved renal blood flow and reduced mean arterial pressure during an infusion of angiotensin II .
16-1	1992-1994	An	abstract[100]	new[100]	coref	22-1[167_100]
16-2	1995-2009	interventional	abstract[100]	new[100]	_	_
16-3	2010-2015	study	abstract[100]	new[100]	_	_
16-4	2016-2028	demonstrated	_	_	_	_
16-5	2029-2033	that	_	_	_	_
16-6	2034-2037	one	time[101]	new[101]	_	_
16-7	2038-2043	month	time[101]	new[101]	_	_
16-8	2044-2046	of	time[101]	new[101]	_	_
16-9	2047-2056	vitamin-D	time[101]|substance|abstract[103]	new[101]|giv|giv[103]	appos|coref	16-12[104_103]|17-3
16-10	2057-2063	intake	time[101]|abstract[103]	new[101]|giv[103]	_	_
16-11	2064-2065	(	_	_	_	_
16-12	2066-2072	1,5000	abstract[104]	giv[104]	coref	17-3[116_104]
16-13	2073-2079	IU/day	abstract[104]	giv[104]	_	_
16-14	2080-2081	)	_	_	_	_
16-15	2082-2089	reduced	_	_	_	_
16-16	2090-2096	tissue	object|abstract[106]	new|new[106]	coref	25-20[204_0]
16-17	2097-2108	sensitivity	abstract[106]	new[106]	_	_
16-18	2109-2111	to	abstract[106]	new[106]	_	_
16-19	2112-2115	the	abstract[106]|event[107]	new[106]|new[107]	_	_
16-20	2116-2127	stimulation	abstract[106]|event[107]	new[106]|new[107]	_	_
16-21	2128-2130	of	abstract[106]|event[107]	new[106]|new[107]	_	_
16-22	2131-2134	the	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	coref	21-22[166_110]
16-23	2135-2140	renin	abstract[106]|event[107]|substance|abstract[110]	new[106]|new[107]|new|new[110]	coref	21-23
16-24	2141-2142	–	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-25	2143-2154	angiotensin	abstract[106]|event[107]|person|abstract[110]	new[106]|new[107]|new|new[110]	coref	16-42[114_0]
16-26	2155-2161	system	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-27	2162-2172	manifested	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-28	2173-2175	by	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-29	2176-2184	improved	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-30	2185-2190	renal	abstract[106]|event[107]|abstract[110]|abstract[111]	new[106]|new[107]|new[110]|new[111]	_	_
16-31	2191-2196	blood	abstract[106]|event[107]|abstract[110]|abstract[111]	new[106]|new[107]|new[110]|new[111]	_	_
16-32	2197-2201	flow	abstract[106]|event[107]|abstract[110]|abstract[111]	new[106]|new[107]|new[110]|new[111]	_	_
16-33	2202-2205	and	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-34	2206-2213	reduced	abstract[106]|event[107]|abstract[110]	new[106]|new[107]|new[110]	_	_
16-35	2214-2218	mean	abstract[106]|event[107]|abstract[110]|abstract[112]	new[106]|new[107]|new[110]|giv[112]	coref	21-13[162_112]
16-36	2219-2227	arterial	abstract[106]|event[107]|abstract[110]|abstract[112]	new[106]|new[107]|new[110]|giv[112]	_	_
16-37	2228-2236	pressure	abstract[106]|event[107]|abstract[110]|abstract[112]	new[106]|new[107]|new[110]|giv[112]	_	_
16-38	2237-2243	during	_	_	_	_
16-39	2244-2246	an	event[113]	new[113]	_	_
16-40	2247-2255	infusion	event[113]	new[113]	_	_
16-41	2256-2258	of	event[113]	new[113]	_	_
16-42	2259-2270	angiotensin	event[113]|person[114]	new[113]|giv[114]	coref	21-25[0_114]
16-43	2271-2273	II	event[113]|person[114]	new[113]|giv[114]	_	_
16-44	2274-2275	.	_	_	_	_

#Text=Moreover , vitamin-D intake ( 2000 IU/day ) for 14 days in healthy adults reduced augmentation index , a measure of arterial stiffness that contributes to the development of hypertension .
17-1	2276-2284	Moreover	_	_	_	_
17-2	2285-2286	,	_	_	_	_
17-3	2287-2296	vitamin-D	substance|abstract[116]	giv|giv[116]	appos|coref	17-6[117_116]|18-4
17-4	2297-2303	intake	abstract[116]	giv[116]	_	_
17-5	2304-2305	(	_	_	_	_
17-6	2306-2310	2000	abstract[117]	giv[117]	_	_
17-7	2311-2317	IU/day	abstract[117]	giv[117]	_	_
17-8	2318-2319	)	_	_	_	_
17-9	2320-2323	for	_	_	_	_
17-10	2324-2326	14	time[118]	new[118]	_	_
17-11	2327-2331	days	time[118]	new[118]	_	_
17-12	2332-2334	in	time[118]	new[118]	_	_
17-13	2335-2342	healthy	time[118]|person[119]	new[118]|new[119]	coref	25-33[206_119]
17-14	2343-2349	adults	time[118]|person[119]	new[118]|new[119]	_	_
17-15	2350-2357	reduced	_	_	_	_
17-16	2358-2370	augmentation	abstract|abstract[121]	new|giv[121]	appos	17-19[122_121]
17-17	2371-2376	index	abstract[121]	giv[121]	_	_
17-18	2377-2378	,	_	_	_	_
17-19	2379-2380	a	abstract[122]	giv[122]	_	_
17-20	2381-2388	measure	abstract[122]	giv[122]	_	_
17-21	2389-2391	of	abstract[122]	giv[122]	_	_
17-22	2392-2400	arterial	abstract[122]|abstract[123]	giv[122]|giv[123]	coref	21-10[160_123]
17-23	2401-2410	stiffness	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
17-24	2411-2415	that	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
17-25	2416-2427	contributes	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
17-26	2428-2430	to	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
17-27	2431-2434	the	abstract[122]|abstract[123]|event[124]	giv[122]|giv[123]|new[124]	_	_
17-28	2435-2446	development	abstract[122]|abstract[123]|event[124]	giv[122]|giv[123]|new[124]	_	_
17-29	2447-2449	of	abstract[122]|abstract[123]|event[124]	giv[122]|giv[123]|new[124]	_	_
17-30	2450-2462	hypertension	abstract[122]|abstract[123]|event[124]|abstract	giv[122]|giv[123]|new[124]|giv	_	_
17-31	2463-2464	.	_	_	_	_

#Text=The discovery of vitamin-D receptor ( VDR ) widened the scope of biological effects that vitamin D plays in human health .
18-1	2465-2468	The	event[126]	new[126]	_	_
18-2	2469-2478	discovery	event[126]	new[126]	_	_
18-3	2479-2481	of	event[126]	new[126]	_	_
18-4	2482-2491	vitamin-D	event[126]|substance|abstract[128]	new[126]|giv|new[128]	appos|coref	18-7[0_128]|23-14
18-5	2492-2500	receptor	event[126]|abstract[128]	new[126]|new[128]	_	_
18-6	2501-2502	(	_	_	_	_
18-7	2503-2506	VDR	abstract	giv	coref	19-1
18-8	2507-2508	)	_	_	_	_
18-9	2509-2516	widened	_	_	_	_
18-10	2517-2520	the	abstract[130]	new[130]	_	_
18-11	2521-2526	scope	abstract[130]	new[130]	_	_
18-12	2527-2529	of	abstract[130]	new[130]	_	_
18-13	2530-2540	biological	abstract[130]|abstract[131]	new[130]|new[131]	coref	25-10[199_131]
18-14	2541-2548	effects	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-15	2549-2553	that	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-16	2554-2561	vitamin	abstract[130]|abstract[131]|substance|person[133]	new[130]|new[131]|giv|giv[133]	coref|coref	19-13[139_0]|24-10[0_133]
18-17	2562-2563	D	abstract[130]|abstract[131]|person[133]	new[130]|new[131]|giv[133]	_	_
18-18	2564-2569	plays	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-19	2570-2572	in	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-20	2573-2578	human	abstract[130]|abstract[131]|abstract[134]	new[130]|new[131]|giv[134]	_	_
18-21	2579-2585	health	abstract[130]|abstract[131]|abstract[134]	new[130]|new[131]|giv[134]	_	_
18-22	2586-2587	.	_	_	_	_

#Text=VDR is a transcription factor that enters the nucleus upon binding to vitamin D , where it attaches to specific DNA regions and activates the transcription of a myriad of genes that coordinate several biological responses .
19-1	2588-2591	VDR	abstract	giv	coref	19-3[137_0]
19-2	2592-2594	is	_	_	_	_
19-3	2595-2596	a	abstract[137]	giv[137]	coref	20-1[0_137]
19-4	2597-2610	transcription	abstract|abstract[137]	new|giv[137]	coref	19-25[143_0]
19-5	2611-2617	factor	abstract[137]	giv[137]	_	_
19-6	2618-2622	that	abstract[137]	giv[137]	_	_
19-7	2623-2629	enters	abstract[137]	giv[137]	_	_
19-8	2630-2633	the	abstract[137]|place[138]	giv[137]|new[138]	_	_
19-9	2634-2641	nucleus	abstract[137]|place[138]	giv[137]|new[138]	_	_
19-10	2642-2646	upon	_	_	_	_
19-11	2647-2654	binding	_	_	_	_
19-12	2655-2657	to	_	_	_	_
19-13	2658-2665	vitamin	substance[139]	giv[139]	ana	19-17[0_139]
19-14	2666-2667	D	substance[139]	giv[139]	_	_
19-15	2668-2669	,	_	_	_	_
19-16	2670-2675	where	_	_	_	_
19-17	2676-2678	it	substance	giv	coref	24-9
19-18	2679-2687	attaches	_	_	_	_
19-19	2688-2690	to	_	_	_	_
19-20	2691-2699	specific	place[142]	new[142]	_	_
19-21	2700-2703	DNA	substance|place[142]	new|new[142]	_	_
19-22	2704-2711	regions	place[142]	new[142]	_	_
19-23	2712-2715	and	_	_	_	_
19-24	2716-2725	activates	_	_	_	_
19-25	2726-2729	the	abstract[143]	giv[143]	_	_
19-26	2730-2743	transcription	abstract[143]	giv[143]	_	_
19-27	2744-2746	of	abstract[143]	giv[143]	_	_
19-28	2747-2748	a	abstract[143]|person[144]	giv[143]|new[144]	_	_
19-29	2749-2755	myriad	abstract[143]|person[144]	giv[143]|new[144]	_	_
19-30	2756-2758	of	abstract[143]|person[144]	giv[143]|new[144]	_	_
19-31	2759-2764	genes	abstract[143]|person[144]|abstract[145]	giv[143]|new[144]|new[145]	_	_
19-32	2765-2769	that	abstract[143]|person[144]|abstract[145]	giv[143]|new[144]|new[145]	_	_
19-33	2770-2780	coordinate	abstract[143]|person[144]|abstract[145]	giv[143]|new[144]|new[145]	_	_
19-34	2781-2788	several	abstract[143]|person[144]|abstract[145]|abstract[146]	giv[143]|new[144]|new[145]|new[146]	_	_
19-35	2789-2799	biological	abstract[143]|person[144]|abstract[145]|abstract[146]	giv[143]|new[144]|new[145]|new[146]	_	_
19-36	2800-2809	responses	abstract[143]|person[144]|abstract[145]|abstract[146]	giv[143]|new[144]|new[145]|new[146]	_	_
19-37	2810-2811	.	_	_	_	_

#Text=VDR is widely expressed throughout the human body in almost all cells and tissues , including vascular smooth muscle cells , cardiomyocytes , and endothelial cells .
20-1	2812-2815	VDR	abstract	giv	coref	21-7
20-2	2816-2818	is	_	_	_	_
20-3	2819-2825	widely	_	_	_	_
20-4	2826-2835	expressed	_	_	_	_
20-5	2836-2846	throughout	_	_	_	_
20-6	2847-2850	the	object[148]	giv[148]	_	_
20-7	2851-2856	human	object[148]	giv[148]	_	_
20-8	2857-2861	body	object[148]	giv[148]	_	_
20-9	2862-2864	in	_	_	_	_
20-10	2865-2871	almost	object[149]	new[149]	coref	20-17[152_149]
20-11	2872-2875	all	object[149]	new[149]	_	_
20-12	2876-2881	cells	object[149]	new[149]	_	_
20-13	2882-2885	and	_	_	_	_
20-14	2886-2893	tissues	object[150]	giv[150]	_	_
20-15	2894-2895	,	object[150]	giv[150]	_	_
20-16	2896-2905	including	object[150]	giv[150]	_	_
20-17	2906-2914	vascular	object[150]|object[152]|object[153]	giv[150]|giv[152]|giv[153]	coref|coref	20-17[153_152]|20-25[155_153]
20-18	2915-2921	smooth	object[150]|object[152]|object[153]	giv[150]|giv[152]|giv[153]	_	_
20-19	2922-2928	muscle	object[150]|object|object[152]|object[153]	giv[150]|new|giv[152]|giv[153]	_	_
20-20	2929-2934	cells	object[150]|object[152]|object[153]	giv[150]|giv[152]|giv[153]	_	_
20-21	2935-2936	,	object[150]|object[153]	giv[150]|giv[153]	_	_
20-22	2937-2951	cardiomyocytes	object[150]|object[153]|object	giv[150]|giv[153]|new	_	_
20-23	2952-2953	,	object[150]|object[153]	giv[150]|giv[153]	_	_
20-24	2954-2957	and	object[150]|object[153]	giv[150]|giv[153]	_	_
20-25	2958-2969	endothelial	object[150]|object[153]|object[155]	giv[150]|giv[153]|giv[155]	_	_
20-26	2970-2975	cells	object[150]|object[153]|object[155]	giv[150]|giv[153]|giv[155]	_	_
20-27	2976-2977	.	_	_	_	_

#Text=Animal studies found that loss of VDR signaling increased arterial stiffness and elevated systolic and diastolic blood pressure , independent of the renin – angiotensin – aldosterone system .
21-1	2978-2984	Animal	abstract[156]	giv[156]	coref	23-1[176_156]
21-2	2985-2992	studies	abstract[156]	giv[156]	_	_
21-3	2993-2998	found	_	_	_	_
21-4	2999-3003	that	_	_	_	_
21-5	3004-3008	loss	event[157]	new[157]	coref	24-35[196_157]
21-6	3009-3011	of	event[157]	new[157]	_	_
21-7	3012-3015	VDR	event[157]|abstract|abstract[159]	new[157]|giv|new[159]	_	_
21-8	3016-3025	signaling	event[157]|abstract[159]	new[157]|new[159]	_	_
21-9	3026-3035	increased	_	_	_	_
21-10	3036-3044	arterial	abstract[160]	giv[160]	coref	22-9[171_160]
21-11	3045-3054	stiffness	abstract[160]	giv[160]	_	_
21-12	3055-3058	and	_	_	_	_
21-13	3059-3067	elevated	abstract[162]	giv[162]	_	_
21-14	3068-3076	systolic	abstract[162]	giv[162]	_	_
21-15	3077-3080	and	abstract[162]	giv[162]	_	_
21-16	3081-3090	diastolic	abstract[162]	giv[162]	_	_
21-17	3091-3096	blood	substance|abstract[162]	giv|giv[162]	_	_
21-18	3097-3105	pressure	abstract[162]	giv[162]	_	_
21-19	3106-3107	,	_	_	_	_
21-20	3108-3119	independent	_	_	_	_
21-21	3120-3122	of	_	_	_	_
21-22	3123-3126	the	abstract[166]	giv[166]	coref	29-2[235_166]
21-23	3127-3132	renin	substance|abstract[166]	giv|giv[166]	_	_
21-24	3133-3134	–	abstract[166]	giv[166]	_	_
21-25	3135-3146	angiotensin	person|abstract[166]	giv|giv[166]	_	_
21-26	3147-3148	–	abstract[166]	giv[166]	_	_
21-27	3149-3160	aldosterone	substance|abstract[166]	new|giv[166]	_	_
21-28	3161-3167	system	abstract[166]	giv[166]	_	_
21-29	3168-3169	.	_	_	_	_

#Text=Another study found that VDR knockout mice have increased arterial stiffness through decreased bioavailability of nitric oxide ( NO ) .
22-1	3170-3177	Another	abstract[167]	giv[167]	coref	25-4[198_167]
22-2	3178-3183	study	abstract[167]	giv[167]	_	_
22-3	3184-3189	found	_	_	_	_
22-4	3190-3194	that	_	_	_	_
22-5	3195-3198	VDR	person|animal[170]	new|new[170]	_	_
22-6	3199-3207	knockout	event|animal[170]	new|new[170]	_	_
22-7	3208-3212	mice	animal[170]	new[170]	_	_
22-8	3213-3217	have	_	_	_	_
22-9	3218-3227	increased	abstract[171]	giv[171]	_	_
22-10	3228-3236	arterial	abstract[171]	giv[171]	_	_
22-11	3237-3246	stiffness	abstract[171]	giv[171]	_	_
22-12	3247-3254	through	_	_	_	_
22-13	3255-3264	decreased	abstract[172]	new[172]	_	_
22-14	3265-3280	bioavailability	abstract[172]	new[172]	_	_
22-15	3281-3283	of	abstract[172]	new[172]	_	_
22-16	3284-3290	nitric	abstract[172]|substance|substance[174]	new[172]|new|new[174]	appos	22-19[0_174]
22-17	3291-3296	oxide	abstract[172]|substance[174]	new[172]|new[174]	_	_
22-18	3297-3298	(	_	_	_	_
22-19	3299-3301	NO	substance	giv	coref	23-26
22-20	3302-3303	)	_	_	_	_
22-21	3304-3305	.	_	_	_	_

#Text=These and other studies proposed that the leading mechanism for the association between vitamin-D deficiency and CVD is related to endothelial dysfunction and impaired endothelial-dependent NO production .
23-1	3306-3311	These	abstract[176]	giv[176]	_	_
23-2	3312-3315	and	abstract[176]	giv[176]	_	_
23-3	3316-3321	other	abstract[176]	giv[176]	_	_
23-4	3322-3329	studies	abstract[176]	giv[176]	_	_
23-5	3330-3338	proposed	_	_	_	_
23-6	3339-3343	that	_	_	_	_
23-7	3344-3347	the	abstract[177]	new[177]	coref	28-5[230_177]
23-8	3348-3355	leading	abstract[177]	new[177]	_	_
23-9	3356-3365	mechanism	abstract[177]	new[177]	_	_
23-10	3366-3369	for	abstract[177]	new[177]	_	_
23-11	3370-3373	the	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-12	3374-3385	association	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-13	3386-3393	between	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-14	3394-3403	vitamin-D	abstract[177]|abstract[178]|substance|abstract[180]|abstract[181]	new[177]|giv[178]|giv|giv[180]|giv[181]	_	_
23-15	3404-3414	deficiency	abstract[177]|abstract[178]|abstract[180]|abstract[181]	new[177]|giv[178]|giv[180]|giv[181]	_	_
23-16	3415-3418	and	abstract[177]|abstract[178]|abstract[181]	new[177]|giv[178]|giv[181]	_	_
23-17	3419-3422	CVD	abstract[177]|abstract[178]|abstract[181]|abstract	new[177]|giv[178]|giv[181]|giv	_	_
23-18	3423-3425	is	_	_	_	_
23-19	3426-3433	related	_	_	_	_
23-20	3434-3436	to	_	_	_	_
23-21	3437-3448	endothelial	abstract[183]	giv[183]	_	_
23-22	3449-3460	dysfunction	abstract[183]	giv[183]	_	_
23-23	3461-3464	and	_	_	_	_
23-24	3465-3473	impaired	abstract[185]	giv[185]	coref	26-17[215_185]
23-25	3474-3495	endothelial-dependent	abstract[185]	giv[185]	_	_
23-26	3496-3498	NO	substance|abstract[185]	giv|giv[185]	coref	26-18
23-27	3499-3509	production	abstract[185]	giv[185]	_	_
23-28	3510-3511	.	_	_	_	_

#Text=Despite this accumulating evidence of the role of vitamin D in vascular function , direct mechanistic evidence of this role in the microvasculature of morbidly obese population and how it might be modified following massive weight loss are largely unexplored .
24-1	3512-3519	Despite	_	_	_	_
24-2	3520-3524	this	abstract[186]	giv[186]	coref	24-15[191_186]
24-3	3525-3537	accumulating	abstract[186]	giv[186]	_	_
24-4	3538-3546	evidence	abstract[186]	giv[186]	_	_
24-5	3547-3549	of	abstract[186]	giv[186]	_	_
24-6	3550-3553	the	abstract[186]|abstract[187]	giv[186]|new[187]	coref	24-19[192_187]
24-7	3554-3558	role	abstract[186]|abstract[187]	giv[186]|new[187]	_	_
24-8	3559-3561	of	abstract[186]|abstract[187]	giv[186]|new[187]	_	_
24-9	3562-3569	vitamin	abstract[186]|abstract[187]|substance	giv[186]|new[187]|giv	ana	24-30
24-10	3570-3571	D	abstract[186]|abstract[187]|person	giv[186]|new[187]|giv	coref	26-6[211_0]
24-11	3572-3574	in	abstract[186]|abstract[187]	giv[186]|new[187]	_	_
24-12	3575-3583	vascular	abstract[186]|abstract[187]|abstract[190]	giv[186]|new[187]|new[190]	coref	26-10[212_190]
24-13	3584-3592	function	abstract[186]|abstract[187]|abstract[190]	giv[186]|new[187]|new[190]	_	_
24-14	3593-3594	,	_	_	_	_
24-15	3595-3601	direct	abstract[191]	giv[191]	_	_
24-16	3602-3613	mechanistic	abstract[191]	giv[191]	_	_
24-17	3614-3622	evidence	abstract[191]	giv[191]	_	_
24-18	3623-3625	of	abstract[191]	giv[191]	_	_
24-19	3626-3630	this	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
24-20	3631-3635	role	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
24-21	3636-3638	in	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
24-22	3639-3642	the	abstract[191]|abstract[192]|substance[193]	giv[191]|giv[192]|new[193]	coref	25-16[201_193]
24-23	3643-3659	microvasculature	abstract[191]|abstract[192]|substance[193]	giv[191]|giv[192]|new[193]	_	_
24-24	3660-3662	of	abstract[191]|abstract[192]|substance[193]	giv[191]|giv[192]|new[193]	_	_
24-25	3663-3671	morbidly	abstract[191]|abstract[192]|substance[193]|animal[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
24-26	3672-3677	obese	abstract[191]|abstract[192]|substance[193]|animal[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
24-27	3678-3688	population	abstract[191]|abstract[192]|substance[193]|animal[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
24-28	3689-3692	and	_	_	_	_
24-29	3693-3696	how	_	_	_	_
24-30	3697-3699	it	substance	giv	coref	25-13[200_0]
24-31	3700-3705	might	_	_	_	_
24-32	3706-3708	be	_	_	_	_
24-33	3709-3717	modified	_	_	_	_
24-34	3718-3727	following	_	_	_	_
24-35	3728-3735	massive	event[196]	giv[196]	coref	25-39[208_196]
24-36	3736-3742	weight	event[196]	giv[196]	_	_
24-37	3743-3747	loss	event[196]	giv[196]	_	_
24-38	3748-3751	are	_	_	_	_
24-39	3752-3759	largely	_	_	_	_
24-40	3760-3770	unexplored	_	_	_	_
24-41	3771-3772	.	_	_	_	_

#Text=The purpose of the current study is to investigate the effects of vitamin D on the microvasculature isolated from both subcutaneous ( SAT ) and visceral adipose tissue ( VAT ) in morbidly obese adults before and after bariatric surgery-induced weight loss .
25-1	3773-3776	The	abstract[197]	new[197]	_	_
25-2	3777-3784	purpose	abstract[197]	new[197]	_	_
25-3	3785-3787	of	abstract[197]	new[197]	_	_
25-4	3788-3791	the	abstract[197]|abstract[198]	new[197]|giv[198]	coref	30-2[236_198]
25-5	3792-3799	current	abstract[197]|abstract[198]	new[197]|giv[198]	_	_
25-6	3800-3805	study	abstract[197]|abstract[198]	new[197]|giv[198]	_	_
25-7	3806-3808	is	_	_	_	_
25-8	3809-3811	to	_	_	_	_
25-9	3812-3823	investigate	_	_	_	_
25-10	3824-3827	the	abstract[199]	giv[199]	coref	30-15[239_199]
25-11	3828-3835	effects	abstract[199]	giv[199]	_	_
25-12	3836-3838	of	abstract[199]	giv[199]	_	_
25-13	3839-3846	vitamin	abstract[199]|substance[200]	giv[199]|giv[200]	coref	26-6[0_200]
25-14	3847-3848	D	abstract[199]|substance[200]	giv[199]|giv[200]	_	_
25-15	3849-3851	on	abstract[199]|substance[200]	giv[199]|giv[200]	_	_
25-16	3852-3855	the	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-17	3856-3872	microvasculature	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-18	3873-3881	isolated	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-19	3882-3886	from	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-20	3887-3891	both	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	appos	25-30[0_204]
25-21	3892-3904	subcutaneous	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-22	3905-3906	(	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-23	3907-3910	SAT	abstract[199]|substance[200]|substance[201]|object|object[204]	giv[199]|giv[200]|giv[201]|new|giv[204]	_	_
25-24	3911-3912	)	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-25	3913-3916	and	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-26	3917-3925	visceral	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-27	3926-3933	adipose	abstract[199]|substance[200]|substance[201]|abstract|object[204]	giv[199]|giv[200]|giv[201]|giv|giv[204]	_	_
25-28	3934-3940	tissue	abstract[199]|substance[200]|substance[201]|object[204]	giv[199]|giv[200]|giv[201]|giv[204]	_	_
25-29	3941-3942	(	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-30	3943-3946	VAT	abstract[199]|substance[200]|substance[201]|object	giv[199]|giv[200]|giv[201]|giv	_	_
25-31	3947-3948	)	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-32	3949-3951	in	abstract[199]|substance[200]|substance[201]	giv[199]|giv[200]|giv[201]	_	_
25-33	3952-3960	morbidly	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	coref	26-13[213_206]
25-34	3961-3966	obese	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	_	_
25-35	3967-3973	adults	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	_	_
25-36	3974-3980	before	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	_	_
25-37	3981-3984	and	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	_	_
25-38	3985-3990	after	abstract[199]|substance[200]|substance[201]|person[206]	giv[199]|giv[200]|giv[201]|giv[206]	_	_
25-39	3991-4000	bariatric	abstract[199]|substance[200]|substance[201]|person[206]|event[208]	giv[199]|giv[200]|giv[201]|giv[206]|giv[208]	coref	26-34[218_208]
25-40	4001-4016	surgery-induced	abstract[199]|substance[200]|substance[201]|person[206]|event[208]	giv[199]|giv[200]|giv[201]|giv[206]|giv[208]	_	_
25-41	4017-4023	weight	abstract[199]|substance[200]|substance[201]|person[206]|place|event[208]	giv[199]|giv[200]|giv[201]|giv[206]|new|giv[208]	_	_
25-42	4024-4028	loss	abstract[199]|substance[200]|substance[201]|person[206]|event[208]	giv[199]|giv[200]|giv[201]|giv[206]|giv[208]	_	_
25-43	4029-4030	.	_	_	_	_

#Text=The central hypothesis is that vitamin D would improve microvascular function in obese adults via improving flow-mediated NO production , and this effect would be of a greater magnitude before compared to after weight loss .
26-1	4031-4034	The	abstract[209]	new[209]	_	_
26-2	4035-4042	central	abstract[209]	new[209]	_	_
26-3	4043-4053	hypothesis	abstract[209]	new[209]	_	_
26-4	4054-4056	is	_	_	_	_
26-5	4057-4061	that	_	_	_	_
26-6	4062-4069	vitamin	substance|person[211]	giv|giv[211]	_	_
26-7	4070-4071	D	person[211]	giv[211]	_	_
26-8	4072-4077	would	_	_	_	_
26-9	4078-4085	improve	_	_	_	_
26-10	4086-4099	microvascular	abstract[212]	giv[212]	coref	30-18[240_212]
26-11	4100-4108	function	abstract[212]	giv[212]	_	_
26-12	4109-4111	in	_	_	_	_
26-13	4112-4117	obese	person[213]	giv[213]	_	_
26-14	4118-4124	adults	person[213]	giv[213]	_	_
26-15	4125-4128	via	_	_	_	_
26-16	4129-4138	improving	_	_	_	_
26-17	4139-4152	flow-mediated	abstract[215]	giv[215]	_	_
26-18	4153-4155	NO	substance|abstract[215]	giv|giv[215]	coref	27-25
26-19	4156-4166	production	abstract[215]	giv[215]	_	_
26-20	4167-4168	,	_	_	_	_
26-21	4169-4172	and	_	_	_	_
26-22	4173-4177	this	abstract[216]	new[216]	_	_
26-23	4178-4184	effect	abstract[216]	new[216]	_	_
26-24	4185-4190	would	_	_	_	_
26-25	4191-4193	be	_	_	_	_
26-26	4194-4196	of	_	_	_	_
26-27	4197-4198	a	abstract[217]	new[217]	_	_
26-28	4199-4206	greater	abstract[217]	new[217]	_	_
26-29	4207-4216	magnitude	abstract[217]	new[217]	_	_
26-30	4217-4223	before	abstract[217]	new[217]	_	_
26-31	4224-4232	compared	abstract[217]	new[217]	_	_
26-32	4233-4235	to	_	_	_	_
26-33	4236-4241	after	_	_	_	_
26-34	4242-4248	weight	event[218]	giv[218]	_	_
26-35	4249-4253	loss	event[218]	giv[218]	_	_
26-36	4254-4255	.	_	_	_	_

#Text=In our previous work , we found that flow-induced dilation ( FID ) is impaired in morbidly obese individuals due to an imbalance of NO and H2O2 .
27-1	4256-4258	In	_	_	_	_
27-2	4259-4262	our	person|abstract[220]	acc|new[220]	ana	27-6
27-3	4263-4271	previous	abstract[220]	new[220]	_	_
27-4	4272-4276	work	abstract[220]	new[220]	_	_
27-5	4277-4278	,	_	_	_	_
27-6	4279-4281	we	person	giv	ana	30-5
27-7	4282-4287	found	_	_	_	_
27-8	4288-4292	that	_	_	_	_
27-9	4293-4305	flow-induced	abstract[222]	new[222]	appos	27-12[0_222]
27-10	4306-4314	dilation	abstract[222]	new[222]	_	_
27-11	4315-4316	(	_	_	_	_
27-12	4317-4320	FID	abstract	giv	_	_
27-13	4321-4322	)	_	_	_	_
27-14	4323-4325	is	_	_	_	_
27-15	4326-4334	impaired	_	_	_	_
27-16	4335-4337	in	_	_	_	_
27-17	4338-4346	morbidly	person[224]	giv[224]	_	_
27-18	4347-4352	obese	person[224]	giv[224]	_	_
27-19	4353-4364	individuals	person[224]	giv[224]	_	_
27-20	4365-4368	due	_	_	_	_
27-21	4369-4371	to	_	_	_	_
27-22	4372-4374	an	abstract[225]	new[225]	_	_
27-23	4375-4384	imbalance	abstract[225]	new[225]	_	_
27-24	4385-4387	of	abstract[225]	new[225]	_	_
27-25	4388-4390	NO	abstract[225]|substance|abstract[227]	new[225]|giv|new[227]	coref|coref	30-21[241_0]|30-21[242_227]
27-26	4391-4394	and	abstract[225]|abstract[227]	new[225]|new[227]	_	_
27-27	4395-4399	H2O2	abstract[225]|abstract[227]|abstract	new[225]|new[227]|new	coref	28-1
27-28	4400-4401	.	_	_	_	_

#Text=H2O2 may serve as a compensatory mechanism for vasodilation during pathological conditions such as obesity .
28-1	4402-4406	H2O2	abstract	giv	coref	30-24
28-2	4407-4410	may	_	_	_	_
28-3	4411-4416	serve	_	_	_	_
28-4	4417-4419	as	_	_	_	_
28-5	4420-4421	a	abstract[230]	giv[230]	_	_
28-6	4422-4434	compensatory	abstract[230]	giv[230]	_	_
28-7	4435-4444	mechanism	abstract[230]	giv[230]	_	_
28-8	4445-4448	for	abstract[230]	giv[230]	_	_
28-9	4449-4461	vasodilation	abstract[230]|event	giv[230]|new	_	_
28-10	4462-4468	during	_	_	_	_
28-11	4469-4481	pathological	abstract[232]	new[232]	_	_
28-12	4482-4492	conditions	abstract[232]	new[232]	_	_
28-13	4493-4497	such	abstract[232]	new[232]	_	_
28-14	4498-4500	as	abstract[232]	new[232]	_	_
28-15	4501-4508	obesity	abstract[232]|abstract	new[232]|giv	_	_
28-16	4509-4510	.	_	_	_	_

#Text=Using the proposed ex vivo system
29-1	4511-4516	Using	_	_	_	_
29-2	4517-4520	the	abstract[235]	giv[235]	_	_
29-3	4521-4529	proposed	abstract[235]	giv[235]	_	_
29-4	4530-4532	ex	organization[234]|abstract[235]	new[234]|giv[235]	_	_
29-5	4533-4537	vivo	organization[234]|abstract[235]	new[234]|giv[235]	_	_
29-6	4538-4544	system	abstract[235]	giv[235]	_	_

#Text=in this study , we are able to explore the contributing vasoactive mediators of vitamin-D effects on microvascular function , mainly NO and H2O2 .
30-1	4545-4547	in	_	_	_	_
30-2	4548-4552	this	abstract[236]	giv[236]	_	_
30-3	4553-4558	study	abstract[236]	giv[236]	_	_
30-4	4559-4560	,	_	_	_	_
30-5	4561-4563	we	person	giv	_	_
30-6	4564-4567	are	_	_	_	_
30-7	4568-4572	able	_	_	_	_
30-8	4573-4575	to	_	_	_	_
30-9	4576-4583	explore	_	_	_	_
30-10	4584-4587	the	person[238]	new[238]	_	_
30-11	4588-4600	contributing	person[238]	new[238]	_	_
30-12	4601-4611	vasoactive	person[238]	new[238]	_	_
30-13	4612-4621	mediators	person[238]	new[238]	_	_
30-14	4622-4624	of	person[238]	new[238]	_	_
30-15	4625-4634	vitamin-D	person[238]|abstract[239]	new[238]|giv[239]	_	_
30-16	4635-4642	effects	person[238]|abstract[239]	new[238]|giv[239]	_	_
30-17	4643-4645	on	person[238]|abstract[239]	new[238]|giv[239]	_	_
30-18	4646-4659	microvascular	person[238]|abstract[239]|abstract[240]	new[238]|giv[239]|giv[240]	_	_
30-19	4660-4668	function	person[238]|abstract[239]|abstract[240]	new[238]|giv[239]|giv[240]	_	_
30-20	4669-4670	,	_	_	_	_
30-21	4671-4677	mainly	substance[241]|abstract[242]	giv[241]|giv[242]	_	_
30-22	4678-4680	NO	substance[241]|abstract[242]	giv[241]|giv[242]	_	_
30-23	4681-4684	and	abstract[242]	giv[242]	_	_
30-24	4685-4689	H2O2	abstract[242]|abstract	giv[242]|giv	_	_
30-25	4690-4691	.	_	_	_	_
